| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5073a0063d6be9e25c14d2af0a1ee89
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d41a7d9056e21e61e70994bb5d7ded8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94462e6d4f62b1381819767daea8cfd3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_112550b1b7fdad030493300629d55245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d44689d6c45d029dce7bd8bd66043414 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-14 |
| filingDate |
2016-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3bdb3f576233dd5b9e862a5af2a7bf8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62dcc4c48df5727666504da5d8a7d662
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebf9c52dfd554da638ef8a97889fca0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_997daddfb54a92ec2a1e5e835024f009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81feca726d033d39d5035c220d1b0dbb |
| publicationDate |
2020-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10617658-B2 |
| titleOfInvention |
Use of hydroxycarbamide for preventing retinal nonperfusion |
| abstract |
The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO. |
| priorityDate |
2015-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |